Lornoxicam

Cat. No.: HY-B0367
CAS No.: 70374-39-9
Molecular Formula: C_{13}H_{10}ClN_{3}O_{4}S_{2}
Molecular Weight: 371.82
Target: COX; Endogenous Metabolite
Pathway: Immunology/Inflammation; Metabolic Enzyme/Protease
Storage: Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO : 3.8 mg/mL (10.22 mM; Need ultrasonic and warming)

Preparing Stock Solutions

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Mass</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.6895 mL</td>
<td>13.4474 mL</td>
<td>26.8947 mL</td>
<td></td>
</tr>
<tr>
<td>5 mM</td>
<td>0.5379 mL</td>
<td>2.6895 mL</td>
<td>5.3789 mL</td>
<td></td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2689 mL</td>
<td>1.3447 mL</td>
<td>2.6895 mL</td>
<td></td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Lornoxicam, a COX-1 and COX-2 inhibitor, is a new nonsteroidal anti-inflammatory drug (NSAID). Target: COX
Lornoxicam showed a balanced inhibition of COX-1/-2 exhibiting the lowest IC50 (0.005 microM/0.008 microM) of the large panel of NSAIDs tested. Lornoxicam showed a marked inhibition of IL-6 formation (IC50 54 microM) while the formation of TNF-alpha, IL-1beta and IL-8 was only moderately affected [1]. Lornoxicam is effective in the treatment of patients with activated osteoarthritis; the analgesic and anti-inflammatory effects of lornoxicam are significantly superior to those of rofecoxib without inferiority in tolerability [2]. Lornoxicam was fully effective for prevention of hyperalgesia [3].

IC50 & Target

<table>
<thead>
<tr>
<th>IC50 &amp; Target</th>
<th>COX-1</th>
<th>COX-2</th>
<th>Human Endogenous Metabolite</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5 nM (IC50 in cells)</td>
<td>45 nM (IC50 in cells)</td>
<td>(Endogenous Metabolite)</td>
</tr>
</tbody>
</table>

REFERENCES

www.MedChemExpress.com
